FusoGen Pharmaceuticals, Inc., founded in 2002, is a leading Chinese biotech company based in Tianjin and Beijing, China. FusoGen is dedicated to the development of novel therapeutics for serious virus infections, such as AIDS and Hepatitis B. Sifuvirtide, an HIV fusion inhibitor, is the leading drug candidate of FusoGen.
An HIV fusion inhibitor under development by FusoGen Pharmaceuticals Inc., Sifuvirtide, has obtained patent applications approved in China and in USA, and also pending in Europe and Japan etc through PCT.
Sifuvirtide, a 36 amino acid peptide drug, was classified as new chemical drugs type 1 (1). Its preclinical study and phase I studies have been completed by December, 2005. Results of cell-based assay showed the inhibition activity of Sifuvirtide has 20-fold better than that of T-20; and results of pharmacokinetics study in phase I clinical trials indicated the half-life of Sifuvirtide was 20 hours and 5-fold longer than that of T-20. Moreover, Sifuvirtide can significantly decrease virus load at a fairly low dose level in HIV infected subject study of phase I clinical trials.
In July, 2006, phase II clinical trials of Sifuvirtide were approved by SFDA. So far, this project has been awarded with national “863” grant twice, and has been supported by Tianjin government for two years as well.
In addition to Sifuvirtide, FusoGen has been developing new drugs for hepatitis B and hepatitis C, using its proprietary platform of computer drug design.
To extend its research capabilities, FusoGen has built FusoLab in Beijing to reach more talent pools and resources.
As an innovative drug company, FusoGen has established close collaborative relationship with laboratories from top research institutions, and has built up a Scientific Advisory Board comprising renowned biopharmaceutical scientists and experts. They help FusoGen establish strong capacities in research and development.
To accommodate its expanding needs, FusoGen is investing $25M to build FusoBiopark in Tianjin. FusoBiopark will comprise an administration building, an R & D center, a manufacture section. Both central and local governments are committed to provide very strong supports. The major investment from China and international VCs will keep on supporting development of FusoGen strongly.
扶素生物技术有限公司，成立于 2002 年，总部设在天津，是一家在中国生物技术领域居于领先地位的企业。扶素生物致力于开发具有自主知识产权的抗重大病毒性感染（如艾滋病、乙肝病毒等）一类创新药物。其中抗艾滋病新药西夫韦肽，为公司发展的最为快速的产品。
公司开发的艾滋病病毒膜融合抑制剂——西夫韦肽，已获得中国和美国专利授权，并通过PCT途径申请了欧洲、日本等国家和地区的专利。经国家知识产权局检索认证，西夫韦肽是我国第一个获得美国专利授权的生物技术药物。
西夫韦肽是一个36个氨基酸的多肽药物，属于国家一类新药。临床前研究及I期临床已 2005年 12 月顺利完成。其中，细胞药效学试验表明其抗艾滋病病毒的效价比美国同类药物T20好20倍；I期临床药代动力学结果显示，西夫韦肽的半衰期为20小时，是T20的5倍； I期临床HIV感染者试验证明西夫韦肽能够在较低的剂量下使病毒载量明显下降。
2006年6月，西夫韦肽顺利获得国家食品药品监督管理局（SFDA）批准，进入II期临床试验。该项目已经两次被纳入国家“十五”863计划，并且连续两年列入天津市重点科技攻关项目。
继西夫韦肽研制成功之后，扶素生物应用自有的计算机药物设计平台，设计出抗乙肝病毒和丙肝病毒的抑制剂。
为了拓展公司的研发能力，确保扶素生物研发处于世界一流水平并为后期发展进行人才储备，扶素生物在北京建立了扶素实验室。
作为自主创新的制药企业，扶素生物与一流研究机构的实验室建立了密切交流合作关系，拥有一支由国内外知名生物医药专家组成的顾问团队，以此为基础，扶素生物具备了超强的研究和开发能力。
为满足发展的需要，扶素生物正在天津投资 2500 万美元兴建一座国际化的集办公楼、研发中心和生产基地为一体的扶素生物园。对此，国家和地方政府都提供了大力支持。公司的融资渠道通畅，国内外的资金支持是扶素生物发展的强大后盾。
完善的沟通渠道，透明化的管理流程，崇尚团队协作和以人为本的人文文化为员工提供良好的学习环境和发展机会，鼓励员工自我发展。
我们将为优秀人员提供优厚待遇及广阔的发展空间。
|
